1. Home
  2. ACNT vs ENGN Comparison

ACNT vs ENGN Comparison

Compare ACNT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ascent Industries Co.

ACNT

Ascent Industries Co.

N/A

Current Price

$13.81

Market Cap

121.5M

Sector

Industrials

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.53

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACNT
ENGN
Founded
1945
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Steel/Iron Ore
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
121.5M
117.2M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
ACNT
ENGN
Price
$13.81
$1.53
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $3.29
AVG Volume (30 Days)
18.2K
★ 801.9K
Earning Date
11-04-2026
09-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 106.72
56.85
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.96
$1.40
52 Week High
$17.92
$12.25

Technical Indicators

Market Signals
Indicator
ACNT
ENGN
Relative Strength Index (RSI) 41.60 33.85
Support Level $13.53 $1.40
Resistance Level $14.50 $1.95
Average True Range (ATR) 0.30 0.09
MACD 0.05 -0.01
Stochastic Oscillator 33.97 3.46

Price Performance

Historical Comparison
ACNT
ENGN

About ACNT Ascent Industries Co.

Ascent Industries Co is a specialty chemicals company focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Its customers are spread across energy, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets. The company's core product portfolio includes surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates, offered in both petroleum-based and bio-based formulations. Geographically, it generates maximum revenue from the United States, followed by Mexico, Canada, Honduras, Colombia, the Netherlands, Costa Rica, Japan, and other markets.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: